Vivosim Labs Inc Revenue Growth Rates (VIVS), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Vivosim Labs Inc   (NASDAQ: VIVS)
 

VIVS's Revenue Growth by Quarter and Year

Vivosim Labs Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

VIVS Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter March -
3rd Quarter December -
2nd Quarter September -
1st Quarter June 0.02
FY 0.02

VIVSs Annual Revenue
Vivosim Labs Inc 's Revenue in the fiscal year 2026 $ 0.13 millions
Vivosim Labs Inc 's Revenue in the fiscal year 2025 $ 0.14 millions
Vivosim Labs Inc 's Revenue in the fiscal year 2024 $ 0.11 millions
Vivosim Labs Inc 's Revenue in the fiscal year 2023 $ 0.37 millions
Vivosim Labs Inc 's Revenue in the fiscal year 2022 $ 1.50 millions




VIVS Revenue first quarter 2025 Y/Y Growth Comment
Vivosim Labs Inc reported drop in Revenue in the first quarter 2025 by -55% to $ 0.02 millions, from the same quarter in 2024.
The fall in the first quarter 2025 Vivosim Labs Inc 's Revenue compares unfavorably to the Company's average Revenue rise of 29.9%.

Looking into first quarter 2025 results within Biotechnology & Pharmaceuticals industry 68 other companies have achieved higher Revenue growth. While Vivosim Labs Inc ' s Revenue meltdown of -55% ranks overall at the positon no. 4207 in the first quarter 2025.


VIVS Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter March - -20 % 66.67 % -81.25 %
3rd Quarter December - 50 % 100 % -92.31 %
2nd Quarter September - 0 % - -
1st Quarter June -55 % 0 % -50 % -
FY   - 0 % 16.67 % -

Financial Statements
Vivosim Labs Inc 's first quarter 2025 Revenue $ 0.02 millions VIVS's Income Statement
Vivosim Labs Inc 's first quarter 2024 Revenue $ 0.04 millions Quarterly VIVS's Income Statement


VIVS Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter March - 33.33 % 150 % 200 %
3rd Quarter December - 0 % -33.33 % -
2nd Quarter September - -25 % -25 % -
1st Quarter June -55 % -20 % 33.33 % -50 %
FY (Year on Year)   - 0 % 16.67 % -


Back to VIVS Growth rate Comparisons >> Back to VIVS Growth rate Comparisons >>


Revenue first quarter 2025 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #69
Healthcare Sector #566
Overall #4207

Revenue Y/Y Growth Statistics
High Average Low
502 % 29.9 % -100 %
 
Revenue first quarter 2025 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #69
Healthcare Sector #566
Overall #4207
Revenue Y/Y Growth Statistics
High Average Low
502 % 29.9 % -100 %
 

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Vivosim Labs Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
486.96 % 21.09 % -100 %
(Dec 31 2013)  


VIVS's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2025 Vivosim Labs Inc disclosed fall in Revenue from the fourth quarter by -55% to $ 0.02 millions, from $ 0.04 millions achived in the previous reporting period.

But that's not important problem, as Vivosim Labs Inc 's Revenue generally seem to plunge in this quarter.

Within Biotechnology & Pharmaceuticals industry 65 other companies have achieved higher Revenue quarter on quarter growth. While Vivosim Labs Inc 's Revenue growth quarter on quarter, overall rank is 3849.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #66
Healthcare Sector #563
Overall #3849
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #66
Healthcare Sector #563
Overall #3849
Revenue Q/Q Growth Statistics
High Average Low
486.96 % 21.09 % -100 %
(Dec 31 2013)  


VIVS's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2025 Vivosim Labs Inc disclosed fall in Revenue from the fourth quarter by -55% to $ 0.02 millions, from $ 0.04 millions achived in the previous reporting period.

But that's not important problem, as Vivosim Labs Inc 's Revenue generally seem to plunge in this quarter.

Within Biotechnology & Pharmaceuticals industry 65 other companies have achieved higher Revenue quarter on quarter growth. While Vivosim Labs Inc 's Revenue growth quarter on quarter, overall rank is 3849.


Vivosim Labs Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 0.11 $ 0.13 $ 0.14 $ 0.14 $ 0.14
Y / Y Revenue Growth (TTM) -21.13 % -9.03 % 16.39 % 35.92 % -
Year on Year Revenue Growth Overall Ranking # 1185 # 426 # # #
Seqeuential Revenue Change (TTM) -14.5 % -7.75 % 1.43 % -1.41 % -1.39 %
Seq. Revenue Growth (TTM) Overall Ranking # 1185 # 426 # # #


Cumulative Revenue growth Comment
Vivosim Labs Inc 's cumulative 12 months Revenue continue to fall, but on the faster rate at -21.13% year on year, at Jun 30 2026 compare to the -9.03% decrease at Mar 31 2026. If the Vivosim Labs Inc 's fiscal year would end at Jun 30 2026, annual Revenue would be $0 millions.

In the Healthcare sector 122 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 426 to 1185.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 23
Healthcare Sector # 123
Overall # 600

Revenue TTM Y/Y Growth Statistics
High Average Low
229.95 %
 39.49 %
-76.85 %
(Dec 31 2016)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 51
Sector # 433
S&P 500 # 3150
Cumulative Revenue growth Comment
Vivosim Labs Inc 's cumulative 12 months Revenue continue to fall, but on the faster rate at -21.13% year on year, at Jun 30 2026 compare to the -9.03% decrease at Mar 31 2026. If the Vivosim Labs Inc 's fiscal year would end at Jun 30 2026, annual Revenue would be $0 millions.

In the Healthcare sector 122 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 426 to 1185.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 23
Healthcare Sector # 123
Overall # 600

Revenue TTM Y/Y Growth Statistics
High Average Low
229.95 %
39.49 %
-76.85 %
(Dec 31 2016)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 51
Sector # 433
S&P 500 # 3150




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
VIVS's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Bio rad Laboratories Inc -0.05%$ -0.046 millions
Seer Inc -0.29%$ -0.289 millions
Dyadic International Inc -0.57%$ -0.568 millions
Teva Pharmaceutical Industries Limited-0.81%$ -0.814 millions
Aytu Biopharma Inc-0.91%$ -0.911 millions
Neuropace Inc -1.32%$ -1.323 millions
Ardent Health Inc -1.40%$ -1.400 millions
Sunshine Biopharma Inc -1.56%$ -1.557 millions
Pacific Biosciences Of California Inc -1.71%$ -1.706 millions
United Therapeutics Corporation-1.92%$ -1.916 millions
Orasure Technologies Inc-1.93%$ -1.930 millions
Pulmonx Corporation-1.93%$ -1.931 millions
Volitionrx Limited-1.97%$ -1.975 millions
Organon and Co -2.26%$ -2.258 millions
Airsculpt Technologies Inc -2.53%$ -2.527 millions
Charles River Laboratories International inc -2.72%$ -2.718 millions
Perrigo Company Plc-3.17%$ -3.171 millions
Zai Lab Limited-3.33%$ -3.333 millions
Vanda Pharmaceuticals Inc -3.92%$ -3.919 millions
Teladoc Health Inc -3.95%$ -3.952 millions
Dentsply Sirona Inc -4.06%$ -4.060 millions
Sanuwave Health Inc -4.18%$ -4.181 millions
Treace Medical Concepts Inc -4.24%$ -4.244 millions
Fortrea Holdings Inc -4.52%$ -4.519 millions
Positron Corporation-6.91%$ -6.907 millions
Standard Biotools Inc -7.05%$ -7.046 millions
Inspire Medical Systems inc -7.32%$ -7.316 millions
Adapthealth Corp -7.50%$ -7.505 millions
China Pharma Holdings Inc-7.55%$ -7.548 millions
Skinhealth Systems Inc -7.68%$ -7.680 millions


About Vivosim Labs Inc Revenue Growth Rates (VIVS), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Vivosim Labs Inc (CIK 1497253).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-346820
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Vivosim Labs Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.